Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson’s disease (PD). The primary objective was to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Svenningsson, Per, Johansson, Anders, Nyholm, Dag, Tsitsi, Panagiota, Hansson, Fredrik, Sonesson, Clas, Tedroff, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283839/
https://www.ncbi.nlm.nih.gov/pubmed/30534585
http://dx.doi.org/10.1038/s41531-018-0071-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283839/
https://www.ncbi.nlm.nih.gov/pubmed/30534585
http://dx.doi.org/10.1038/s41531-018-0071-3

Ejemplares similares